The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis; 2) vaccines to prevent HIV; and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will continue its productivity through active engagement with a diverse host of at risk and HIV-impacted communities, participation in high impact, ground-breaking clinical research studies, efficient management of resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU includes CRSs and personnel that have long term and productive involvement with three of the research networks; the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their network affiliations include: Northwestern University (adult HIV therapeutic strategies); University of Illinois Chicago (vaccines to prevent HIV, integrated HIV prevention). Rush University (adult HIV therapeutic strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health & Wellness Center (adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of the major urban HIV epicenters.
The aims of this proposal are: development, implementation and adaptation of the clinical research program of the 1) Adult HIV Therapeutics Strategy, Network, 2) the Vaccines to Prevent HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional, engagement of the relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well positioned to reach diverse populations and contribute significantly to the NIAID research agenda.
The phenomenal scientific advances in HIV/AIDS research over the past 30 years have in large part been due to NIAID's high-impact therapeutic and prevention studies being performed by its clinical trials units (CTUs). The Chicago CTU will continue to respond rapidly to emerging clinical research needs, engage constituents, and identify more effective treatment and prevention strategies.
|La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58|
|Koita, Ousmane A; Murphy, Robert L; Fongoro, SaharÃ© et al. (2016) Clinical Research and the Training of Host Country Investigators: Essential Health Priorities for Disease-Endemic Regions. Am J Trop Med Hyg 94:253-7|
|Bedimo, Roger; Kang, Minhee; Tebas, Pablo et al. (2016) Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Res Hum Retroviruses 32:325-8|
|Weinberg, Adriana; Park, Jeong-Gun; Bosch, Ronald et al. (2016) Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. J Acquir Immune Defic Syndr 71:137-45|
|Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60|
|Kelesidis, Theodoros; Moser, Carlee; Stein, James H et al. (2016) Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis 214:748-52|
|Maiga, Mamoudou; Cohen, Keira; Baya, Bocar et al. (2016) Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali. J Breath Res 10:036012|
|Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68|
|McComsey, Grace A; Moser, Carlee; Currier, Judith et al. (2016) Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis 62:853-62|
|Mathad, Jyoti S; Gupte, Nikhil; Balagopal, Ashwin et al. (2016) Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr 73:123-9|
Showing the most recent 10 out of 105 publications